-
Mashup Score: 51Ductal carcinoma in situ of the breast: finding the balance between overtreatment and undertreatment - 12 month(s) ago
Ductal carcinoma in situ (DCIS) accounts for 15–25% of all breast cancer diagnoses. Its prognosis is excellent overall, the main risk being the occurrence of local breast events, as most cases of DCIS do not progress to invasive cancer. Systematic screening has greatly increased the incidence of this non-obligate precursor of invasion, lending urgency to the need to identify DCIS that is prone to invasive progression and distinguish it from non-invasion-prone DCIS, as the latter can be overdiagnosed and therefore overtreated.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 42ESMO Virtual Plenary with AACR Expert Commentary: May 2024 - 1 year(s) ago
The ESMO Virtual Plenaries are freely available to all healthcare professionals working in Oncology.
Source: www.esmo.orgCategories: General Medicine News, Hem/OncsTweet-
Two phase III randomized trials in metastatic BC and GIST will be presented next week during the @myESMO Virtual Plenary sessions in partnership with @AACR . May 9th or 10th https://t.co/mvhFPDsgnN
-
-
Mashup Score: 31Soutenez Gustave Roussy - 1 year(s) ago
Chers amis, famille, et supporters, Je suis très heureux de vous annoncer que j’ai décidé de courir le Semi-Marathon de Paris 2024, et pas seulement pour le défi sportif. J’ai choisi de courir avec un Dossard Solidaire pour Gustave Roussy, une cause…
Categories: General Medicine News, Hem/OncsTweet-
Ce dimanche, je courrai (lentement…) le semi marathon avec un dossard « Don @GustaveRoussy « . Si certains d’entre vous veulent participer via un don ca serait genial 👇. https://t.co/NMWLKuxRur
-
-
Mashup Score: 47
This first randomised trial supports the use of sunitinib as the medical option with the highest level of evidence for anti-tumour efficacy in progressive metastatic phaeochromocytomas and paragangliomas.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet-
In @TheLancet : Sunitinib is an option in pts w mets phaeochromocytomas and paragangliomas : 36% of pts free of progressive disease at 12 months. 1st randomized trial ever in this disease, by E Baudin @GustaveRoussy and col ENDOCAN-COMET & ENSAT networks. https://t.co/Y3pSVgIpc6
-
-
Mashup Score: 58Academic Positions - 1 year(s) ago
Career network for academics, researchers and scientists. Find and apply for jobs in research and higher education today!
Source: academicpositions.comCategories: General Medicine News, Hem/OncsTweet-
.@GustaveRoussy is recruiting a Clinical Investigator / Physician Scientist in Immuno-Oncology, Early Drug Development Center (DITEP). Speaking French is not mandatory at the time of recruitment. https://t.co/AZuh3IiF9N
-
-
Mashup Score: 53
Checkpoint inhibitors are standard adjuvant treatment for stage IIB–IV resected melanoma, but many patients recur. Our study aimed to evaluate whether…
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet-
Individualised neoantigen therapy mRNA-4157 plus pembrolizumab vs pembro in patients with resected melanoma: a phase II randomized trial. Quite promising data ! Developing the optimal methods to select the relevant neoantigens is becoming a major stake. https://t.co/R92FcdIDC3
-
-
Mashup Score: 30Gustave Roussy hiring Directeur Exécutif IHU PRISM H/F in Villejuif, Île-de-France, France | LinkedIn - 1 year(s) ago
Posted 5:12:30 PM. L’espoir de guérir le cancer a un nom, Gustave Roussy.Premier centre européen de lutte contre le…See this and similar jobs on LinkedIn.
Source: www.linkedin.comCategories: General Medicine News, Hem/OncsTweet-
We are looking for an Executive Director for the Precision Medicine Center PRISM. Please apply to the link below ! https://t.co/r4pUAxZ9Vj
-
-
Mashup Score: 157The need for pragmatic, affordable, and practice-changing real-life clinical trials in oncology - 1 year(s) ago
Thanks to technological advances and improved understanding of cancer biology, clinical research in oncology has become increasingly complex. Trials testing novel interventions are subject to restrictive inclusion criteria, growing infrastructure required for molecular testing or safe delivery of complex biotherapeutics and administrative burden of regulatory requirements for approval of novel therapeutics, and prohibitive costs. Many trials test strategies that cannot be optimally implemented in diverse real-world settings due to technological or funding issues.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet-
Aside trials testing Innovations, there is a need for trials testing pragmatic questions in oncology. These trials must ↘️↘️ the nb of data collected & bureaucracy. This is 1 of the 4 pillars of clinical research strategy @GustaveRoussy 1/2 https://t.co/aqMuvtI6zt
-
-
Mashup Score: 157The need for pragmatic, affordable, and practice-changing real-life clinical trials in oncology - 1 year(s) ago
Thanks to technological advances and improved understanding of cancer biology, clinical research in oncology has become increasingly complex. Trials testing novel interventions are subject to restrictive inclusion criteria, growing infrastructure required for molecular testing or safe delivery of complex biotherapeutics and administrative burden of regulatory requirements for approval of novel therapeutics, and prohibitive costs. Many trials test strategies that cannot be optimally implemented in diverse real-world settings due to technological or funding issues.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet-
Aside trials testing Innovations, there is a need for trials testing pragmatic questions in oncology. These trials must ↘️↘️ the nb of data collected & bureaucracy. This is 1 of the 4 pillars of clinical research strategy @GustaveRoussy 1/2 https://t.co/aqMuvtI6zt
-
-
Mashup Score: 148The need for pragmatic, affordable, and practice-changing real-life clinical trials in oncology - 1 year(s) ago
Thanks to technological advances and improved understanding of cancer biology, clinical research in oncology has become increasingly complex. Trials testing novel interventions are subject to restrictive inclusion criteria, growing infrastructure required for molecular testing or safe delivery of complex biotherapeutics and administrative burden of regulatory requirements for approval of novel therapeutics, and prohibitive costs. Many trials test strategies that cannot be optimally implemented in diverse real-world settings due to technological or funding issues.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet-
Aside trials testing Innovations, there is a need for trials testing pragmatic questions in oncology. These trials must ↘️↘️ the nb of data collected & bureaucracy. This is 1 of the 4 pillars of clinical research strategy @GustaveRoussy 1/2 https://t.co/aqMuvtI6zt
-
In this review @TheLancet , S Delaloge @GustaveRoussy & coll discuss how risk assessment could improve the quality of care in pts with in situ breast carcinoma. This risk-based approach is the foundation of modern cancer prevention centers https://t.co/gYQo7LvKvH